INVO Fertility (IVF) AI Stock Analysis

• Market Cap: $4.45M
• Dividend Yield: N/A
• Average Volume (3M): 810.91K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.41
• Revenue Growth: 14.74%
• EPS Growth: -2.42%
• Country: US
• Employees: 33
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Healthcare Plans
• EPS (TTM): -12.53
• Shares Outstanding: 4,363,016
• 10 Day Avg. Volume: 362,150
• 30 Day Avg. Volume: 810,909
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 3.99
• Enterprise Value/Revenue: 2.68
• Enterprise Value/Gross Profit: 7.00
• Enterprise Value/Ebitda: -0.74
• 1Y Price Target: $1.50
• Price Target Upside: 47.06% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: $1.50 ▲(47.06% Upside)

The overall stock score is primarily impacted by poor financial performance and bearish technical indicators. The company's significant operational losses and high leverage pose substantial risks. The negative P/E ratio and lack of dividend yield further weaken the valuation. Despite a positive corporate event, the overall outlook remains challenging.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates increasing demand for its fertility services, which could lead to improved market positioning and long-term business expansion.

Capital Structure Expansion

The significant increase in authorized shares provides INVO Fertility with greater flexibility for future capital raising, supporting potential growth initiatives and strategic investments.

Institutional Investor Confidence

The exercise of investment rights by an institutional investor signals confidence in INVO Fertility's future prospects, potentially enhancing its financial stability and market credibility.

Negative Factors

High Leverage

High leverage indicates reliance on debt financing, which can limit financial flexibility and increase risk, potentially affecting long-term sustainability.

Operational Losses

Ongoing operational losses highlight challenges in achieving profitability, which may require strategic adjustments to improve financial performance and ensure long-term viability.

Negative Cash Flow

Negative cash flow from operations suggests insufficient cash generation, necessitating reliance on external financing, which could strain resources and impact future growth opportunities.

INVO Fertility Business Overview & Revenue Model

Company Description

INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care. The company focuses on building, acquiring, and operating fertility clinics, including “INVO Centers” offering the intravaginal culture (IVC) procedure enabled by its proprietary INVOcell® medical device. This device allows fertilization and early embryo development to occur in vivo within the woman’s body, providing a more natural, intimate, and affordable alternative to traditional IVF. INVO Fertility operates multiple centers in the U.S. and distributes the INVOcell technology to third-party clinics. The company separated its fertility and oncology businesses in April 2025 to focus exclusively on fertility care.

How the Company Makes Money

INVO Fertility generates revenue primarily through its IVF and fertility treatment services. The company charges patients for various procedures, including consultations, diagnostics, egg retrieval, embryo transfer, and laboratory services. Additionally, INVO Fertility offers fertility preservation services, such as egg freezing and sperm banking, which also contribute to its revenue streams. The company may have partnerships with insurance providers, allowing them to accept certain insurance plans that cover fertility treatments, thus broadening their patient base. Furthermore, INVO Fertility could engage in research collaborations or clinical trials, potentially providing additional funding or revenue opportunities through partnerships with pharmaceutical companies or medical institutions.

INVO Fertility Financial Statement Overview

Summary

INVO Fertility is experiencing revenue growth, but this is offset by significant operational losses and high leverage. The company faces ongoing challenges with profitability and cash flow management, reflecting a need for strategic improvements to enhance financial stability and operational efficiency.

Income Statement

INVO Fertility has shown significant revenue growth over the last year, with a revenue increase from $3.02M in 2023 to $6.53M in 2024. However, the company's gross profit margin decreased, and it continues to operate at a loss, with a net loss of $9.10M in 2024. EBIT and EBITDA margins are negative, indicating ongoing operational challenges.

Balance Sheet

The balance sheet highlights a concerning debt-to-equity ratio as total debt significantly exceeds stockholders' equity. Although the company has managed to increase its total assets, it remains highly leveraged with a debt-to-equity ratio of 0.78. The equity ratio is low, reflecting a reliance on debt financing and potential risk in terms of financial stability.

Cash Flow

INVO Fertility's cash flow statement reveals negative operating cash flows, although there was an improvement in free cash flow from -$5.20M in 2023 to -$3.16M in 2024. The operating cash flow to net income ratio is negative, indicating insufficient cash generation relative to net losses. The company remains reliant on external financing to support its cash flow needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.62M	6.53M	3.02M	822.20K	4.16M	1.04M
Gross Profit	2.54M	2.87M	1.09M	-28.57K	4.02M	948.53K
EBITDA	-23.99M	-7.14M	-6.88M	-10.75M	-5.22M	-5.48M
Net Income	-27.94M	-9.10M	-8.03M	-10.89M	-6.65M	-8.35M
Balance Sheet
Total Assets	19.32M	46.45M	18.51M	3.71M	10.47M	10.95M
Cash, Cash Equivalents and Short-Term Investments	549.18K	741.40K	232.42K	90.14K	5.68M	10.10M
Total Debt	7.13M	9.90M	6.30M	2.27M	2.12M	775.02K
Total Liabilities	16.69M	33.70M	17.61M	4.69M	3.16M	5.20M
Stockholders Equity	2.63M	12.75M	892.60K	-977.61K	7.31M	5.74M
Cash Flow
Free Cash Flow	-6.62M	-3.16M	-5.20M	-6.62M	-6.48M	-4.86M
Operating Cash Flow	-6.52M	-2.97M	-4.76M	-6.60M	-6.03M	-4.78M
Investing Cash Flow	363.04K	363.89K	-2.49M	-81.22K	-2.15M	-187.25K
Financing Cash Flow	5.76M	3.12M	7.39M	1.09M	3.77M	13.82M

INVO Fertility Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVF, the sentiment is Negative. The current price of 1.02 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.76, and below the 200-day MA of 10.60, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 36.28 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVF.

INVO Fertility Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$8.02B	-0.39	-43.38%	2.20%	22.34%	-2.13%
HSDT	45 Neutral	$7.90M	―	-344.28%	―	-50.34%	75.15%
VTAK	44 Neutral	$3.07M	―	-179.11%	―	37.61%	68.37%
TIVC	43 Neutral	$4.83M	―	-160.96%	―	-58.49%	84.67%
IVF	38 Underperform	$4.45M	―	-1294.96%	―	14.74%	-2.42%
BBLG	―	$3.59M	―	-88.80%	―	―	―
BJDX	29 Underperform	$2.17M	―	-96.69%	―	―	98.25%

INVO Fertility Corporate Events

INVO Fertility Amends Financial Agreement with Five Narrow Lane

On August 21, 2025, INVO Fertility, Inc. and Five Narrow Lane LP amended their financial agreement, reducing the principal amount of a debenture and exchanging it for preferred stock shares. Additionally, they extended deadlines for filing and effectiveness of a registration statement with the SEC, impacting the company’s financial operations and stakeholder interests.

INVO Fertility’s Recent Unregistered Equity Sale

On July 28, 2025, an institutional investor of INVO Fertility exercised its right to acquire 200 shares of Series C-2 Convertible Preferred Stock for $200,000, adjusting the conversion price to $1.8909 per share. This transaction was conducted without public offering registration, potentially impacting the company’s financial structure and market positioning.

INVO Fertility Investor Exercises Additional Investment Right

On July 17, 2025, an institutional investor exercised its Additional Investment Right to acquire 200 shares of INVO Fertility‘s Series C-2 Convertible Preferred Stock for $200,000, adjusting the conversion price post-split to $1.9953 per share. Additionally, during the company’s annual meeting, stockholders approved an amendment to increase the authorized shares of common stock from 1,388,888 to 50,000,000, reflecting a significant expansion in the company’s capital structure.

INVO Fertility Implements Reverse Stock Split

On July 21, 2025, INVO Fertility implemented a 1-for-3 reverse stock split of its common stock to comply with Nasdaq’s minimum bid price requirement. This adjustment, which consolidated every three shares into one, aimed to maintain the company’s listing on The Nasdaq Capital Market, although compliance is not guaranteed.

INVO Fertility Adjourns Stockholder Meeting to July 23

On June 25, 2025, INVO Fertility, Inc. held its annual meeting of stockholders where several proposals were voted on, except for proposal 3. The meeting was adjourned and later reconvened on July 9, 2025, but was again adjourned to July 23, 2025, to address proposal 3, with the meeting set to be held virtually.

INVO Fertility Amends Securities Purchase Agreement

On June 30, 2025, NAYA Therapeutics Inc. amended its Securities Purchase Agreement with an institutional investor, allowing the investor to purchase additional shares of Series C-2 Convertible Preferred Stock or exchange them for a portion of the company’s debenture. This amendment aims to provide flexibility in investment options and potentially impact the company’s financial structure and market positioning. Additionally, the company entered into an AIR Exercise and Reload Agreement, resulting in the issuance of new unregistered C-2 Preferred shares and restrictions on certain stock transactions for a specified period, which could influence the company’s stock issuance strategy and shareholder value.

INVO Fertility Adjourns Meeting to Solicit Votes

On June 25, 2025, INVO Fertility, Inc. held its annual meeting of stockholders where several proposals were voted on. The meeting was adjourned to July 9, 2025, to further solicit votes on a proposal to increase the number of authorized shares. Key approvals included the election of directors, ratification of the company’s accountant, and several stock issuance proposals under Nasdaq rules, which could impact the company’s capital structure and strategic flexibility.